BRPI0919034A8 - Métodos para produzir uma proteína e um anticorpo, meio líquido aquoso para cultura, e, vaso - Google Patents

Métodos para produzir uma proteína e um anticorpo, meio líquido aquoso para cultura, e, vaso

Info

Publication number
BRPI0919034A8
BRPI0919034A8 BRPI0919034A BRPI0919034A BRPI0919034A8 BR PI0919034 A8 BRPI0919034 A8 BR PI0919034A8 BR PI0919034 A BRPI0919034 A BR PI0919034A BR PI0919034 A BRPI0919034 A BR PI0919034A BR PI0919034 A8 BRPI0919034 A8 BR PI0919034A8
Authority
BR
Brazil
Prior art keywords
methods
antibody
protein
vessel
producing
Prior art date
Application number
BRPI0919034A
Other languages
English (en)
Inventor
Krishnan Rajesh
Rendeiro Dennis
Sandadi Sandeepa
Original Assignee
Schering Corp
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Merck Sharp & Dohme filed Critical Schering Corp
Publication of BRPI0919034A2 publication Critical patent/BRPI0919034A2/pt
Publication of BRPI0919034A8 publication Critical patent/BRPI0919034A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0043—Medium free of human- or animal-derived components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0056—Xeno-free medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/76—Undefined extracts from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/33—Insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

MÉTODOS PARA PRODUZIR UMA PROTEÍNA E UM ANTICORPO, MEIO LÍQUIDO AQUOSO PARA CULTURA, E, VASO. A presente invenção fornece, em parte, métodos para expressar recombinantemente proteínas em um nível alto junto com meios de cultura de células para realizar o mesmo.
BRPI0919034A 2008-09-26 2009-09-24 Métodos para produzir uma proteína e um anticorpo, meio líquido aquoso para cultura, e, vaso BRPI0919034A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10045008P 2008-09-26 2008-09-26
PCT/US2009/058164 WO2010036767A1 (en) 2008-09-26 2009-09-24 High titer antibody production

Publications (2)

Publication Number Publication Date
BRPI0919034A2 BRPI0919034A2 (pt) 2015-08-18
BRPI0919034A8 true BRPI0919034A8 (pt) 2016-02-10

Family

ID=41334376

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0919034A BRPI0919034A8 (pt) 2008-09-26 2009-09-24 Métodos para produzir uma proteína e um anticorpo, meio líquido aquoso para cultura, e, vaso

Country Status (14)

Country Link
US (1) US20110229933A1 (pt)
EP (1) EP2342318A1 (pt)
JP (1) JP2012503487A (pt)
KR (1) KR20110060911A (pt)
CN (1) CN102224239A (pt)
AU (1) AU2009296708A1 (pt)
BR (1) BRPI0919034A8 (pt)
CA (1) CA2737580A1 (pt)
CO (1) CO6351809A2 (pt)
IL (1) IL211639A0 (pt)
MX (1) MX2011003241A (pt)
NZ (1) NZ591651A (pt)
RU (1) RU2011116319A (pt)
WO (1) WO2010036767A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
NZ597692A (en) 2008-12-12 2013-08-30 Boehringer Ingelheim Int Anti-IGF antibodies
RU2563353C2 (ru) * 2010-04-26 2015-09-20 Новартис Аг Улучшенная среда для культивирования клеток
KR101591671B1 (ko) 2011-04-29 2016-02-04 바이오콘 리서치 리미티드 항체의 이질성을 감소시키는 방법 및 그 항체의 제조방법
CN103797110B (zh) 2011-07-12 2017-08-25 食品安全测试系统公司 沙门氏菌和大肠杆菌的培养基和培养方法以及用于检测沙门氏菌和大肠杆菌的方法
US20130281355A1 (en) * 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
WO2014054744A1 (ja) * 2012-10-03 2014-04-10 協和発酵キリン株式会社 培養液にアミノ酸を添加することによるポリペプチドの還元防止方法
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
AU2014233393B2 (en) * 2013-03-15 2020-05-28 Genentech, Inc. Cell culture compositions with antioxidants and methods for polypeptide production
AR095196A1 (es) * 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
ITTO20130493A1 (it) * 2013-06-14 2014-12-15 Determinants Of Metabolism Res Lab S R L Composizione per l'eliminazione di animali molesti infestanti
CN104212769B (zh) * 2014-07-14 2017-05-10 北京益生合生物科技有限公司 一种用于高产单抗的细胞培养基添加剂
WO2016153983A1 (en) * 2015-03-20 2016-09-29 Bristol-Myers Squibb Company Use of dextran for protein purification
JP6744324B2 (ja) * 2015-04-01 2020-08-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 細胞培養培地
GB201506869D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
DK3305891T3 (da) 2015-05-27 2021-01-25 Astellas Pharma Inc Celledyrkningsfremgangsmåde som anvender nukleinsyre-holdigt medium
HU231463B1 (hu) * 2015-08-04 2024-01-28 Richter Gedeon Nyrt. Módszer rekombináns proteinek galaktóz tartalmának növelésére
TWI870789B (zh) 2015-08-04 2025-01-21 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
CN107460221B (zh) * 2016-06-02 2021-01-15 正大天晴药业集团股份有限公司 一种降低抗pd-l1抗体中蛋白聚合物的细胞培养方法
WO2018018613A1 (zh) 2016-07-29 2018-02-01 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
CN106479982A (zh) * 2016-10-17 2017-03-08 深圳万乐药业有限公司 抗pd‑1单克隆抗体生产用细胞培养基及其优化方法
JP2018113907A (ja) * 2017-01-18 2018-07-26 株式会社Ｒｅｇｅｎｅ Ｐｈａｒｍ 動物細胞の培養方法
EP3635093A1 (en) 2017-06-08 2020-04-15 Polpharma Biologics S.A. Improved methods of cell culture
EP3647411A4 (en) * 2017-06-27 2021-05-12 Ajinomoto Co., Inc. MEDIUM CONTAINING A RIBOFLAVIN DERIVATIVE
US10961500B1 (en) * 2019-04-23 2021-03-30 Regeneron Pharmaceuticals, Inc. Cell culture medium for eukaryotic cells
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
SG11202110968VA (en) 2019-12-06 2021-10-28 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
AU2021268026A1 (en) 2020-05-08 2023-01-19 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
US20220267450A1 (en) 2020-10-14 2022-08-25 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
CN113117455B (zh) * 2021-04-12 2022-11-22 江西师范大学 氯化胆碱-甘油低共熔溶剂在吸收HCl气体中的应用
EP4384219A4 (en) 2021-08-10 2025-06-18 Viridian Therapeutics, Inc. COMPOSITIONS, DOSAGES AND METHODS FOR THE TREATMENT OF THYROID EYE DISEASE
US20250188438A1 (en) 2022-03-08 2025-06-12 CONNEXT Co.,Ltd Composition comprising collagenase, calcium, histidine, and glycine, and method for stabilizing collagenase
CN115369069B (zh) * 2022-08-22 2023-12-19 上海健士拜生物科技有限公司 293细胞补料培养基及其制备和应用
CN119351502B (zh) * 2024-12-25 2025-05-13 正大天晴药业集团股份有限公司 抗体的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT409379B (de) * 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
EP1210411B1 (en) * 1999-08-25 2006-10-18 Immunex Corporation Compositions and methods for improved cell culture
EP1506286B1 (en) * 2002-05-24 2014-03-19 Merck Sharp & Dohme Corp. Neutralizing human anti-igfr antibody

Also Published As

Publication number Publication date
IL211639A0 (en) 2011-05-31
NZ591651A (en) 2012-12-21
MX2011003241A (es) 2011-04-21
US20110229933A1 (en) 2011-09-22
JP2012503487A (ja) 2012-02-09
WO2010036767A1 (en) 2010-04-01
EP2342318A1 (en) 2011-07-13
RU2011116319A (ru) 2012-11-10
CA2737580A1 (en) 2010-04-01
BRPI0919034A2 (pt) 2015-08-18
CN102224239A (zh) 2011-10-19
CO6351809A2 (es) 2011-12-20
KR20110060911A (ko) 2011-06-08
AU2009296708A1 (en) 2010-04-01

Similar Documents

Publication Publication Date Title
BRPI0919034A8 (pt) Métodos para produzir uma proteína e um anticorpo, meio líquido aquoso para cultura, e, vaso
CR20120371A (es) Antagonistas de pcsk9
BRPI0911038A2 (pt) métodos para expressar uma sequência heteróloga em uma célula hospedeira e para produzir um isoprenóide em uma célula hospedeira, célula hospedeira, vetor de expressão, conjunto de vetores de expressão, kit, e, cultura celular.
BRPI0916964A2 (pt) polipetídeo, anticorpo, ácido nucléico, vetor, célula hospedeira, método para produzir um polipeptídeo, composição e uso do polipeptídeo
BRPI0914855A2 (pt) dispositivo de controle para dispositivo de exibição de cristal líquido, dispositivo de exibição de cristal líquido, método para controle de dispositivo de exibição de cristal líquido, programa e meio de armazenameto.
BRPI0816094A2 (pt) Anticorpo, polipeptídeo, hibridoma, composição farmacêutica, método para inibir o desenvolvimento de tumor em um mamífero, polinucleotídeo, célula hospedeira, e, método para produzir um anticorpo.
BRPI0618449A2 (pt) métodos para produção de isoformas de receptor e ligante
EP2808393A3 (en) Fucosylation-deficient cells
BR112012026379A2 (pt) métodos para gerar proteína endogenamente marcada
MX2022008013A (es) Estabilizacion de polipeptidos que contienen fragmentos cristalizables.
MX353382B (es) Moleculas de union polipeptido de larga duracion.
CL2013002361A1 (es) Metodo para medir actividad de células natural killer (nk); kit para medir dicha actividad; proteína de fusión; composicion para activar células nk; polipéptido, oligonucleótido, vector y célula hospedera que comprenden la proteína;
BR112014006405A2 (pt) anticorpo, conjunto, e, método para medir um complexo de afinidade
BR112012004856A2 (pt) aparelho de acesso condicional, aparelho fonte, método para gerar seletivamente um sinal com um aparelho de acesso condicional, e, meio de armazenamento legível por computador.
EP2576626A4 (en) STABLE, FUNCTIONAL AND CHIMERIC CELL BIOHYDROLASE ENZYMES OF CLASS 1
WO2007130543A3 (en) Method for producing stable mammalian cell lines producing high levels of recombinant proteins
EP2530290A4 (en) Method for determining fuel quality, program, computer readable recording medium having the program stored thereupon, and device for determining fuel quality
WO2008034622A3 (en) A method of detecting and/or quantifying expression of a target protein candidate in a cell, and a method of identifying a target protein of a small molecule modulator
WO2013081471A3 (en) Facile laboratory method for localising biomolecules to the surface of cells and viruses
MX2016005572A (es) Uso de monensina para regular la glicosilacion de proteinas recombinantes.
AU2018276376A1 (en) Cell culture methods
WO2011145126A3 (en) A method for the preparation of conjugates based on transglutaminase
WO2008090290A3 (fr) Milieu de culture synthétique chimiquement défini
BRPI0920987A2 (pt) método para reproduzir conteúdo, aparelho para reproduzir conteúdo, e meio de gravação legível por computador.
WO2009125999A8 (en) Human host cell for producing recombinant proteins with high quality and quantity

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B25G Requested change of headquarter approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.